Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells

European Journal of Pharmacology

Volumn 591, Issue 1-3, 2008, Pages 219-223

  Li, Manxiang ^a,b   Li, Zongfang ^a   Sun, Xiuzhen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Angiotensin II; Endothelin 1; MMP2; RhoA ROCK; Simvastatin

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANGIOTENSIN II; ENDOTHELIN 1; GELATINASE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INACTIVATION; GENE SILENCING; HYPOXIA; LUNG BLOOD FLOW; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SIMVASTATIN;

EID: 48749119802     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.06.082     Document Type: Article

References (28)

1. Arciniegas E., Frid M.G., Douglas I.S., and Stenmark K.R. Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 293 (2007) L1-8
2. Armitage J. The safety of statins in clinical practice. Lancet 370 (2007) 1781-1790
3. Bohm F., and Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc. Res. 76 (2007) 8-18
4. Bruegel M., Teupser D., Haffner I., Mueller M., and Thiery J. Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin. Exp. Pharmacol. Physiol. 33 (2006) 1144-1149
5. Case D., Irwin D., Ivester C., Harral J., Morris K., Imamura M., Roedersheimer M., Patterson A., Carr M., Hagen M., Saavedra M., Crossno Jr. J., Young K.A., Dempsey E.C., Poirier F., West J., and Majka S. Mice deficient in galectin-1 exhibit attenuated physiological responses to chronic hypoxia-induced pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L154-164
6. Cowan K.N., Jones P.L., and Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J. Clin. Invest. 105 (2000) 21-34
7. Frisdal E., Gest V., Vieillard-Baron A., Levame M., Lepetit H., Eddahibi S., Lafuma C., Harf A., Adnot S., and Dortho M.P. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur. Respir. J. 18 (2001) 838-845
8. Girgis R.E., Mozammel S., Champion H.C., Li D., Peng X., Shimoda L., Tuder R.M., Johns R.A., and Hassoun P.M. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Lung Cell Mol. Physiol. 292 (2007) L1105-1110
9. Golovina V.A., and Blaustein M.P. Preparation of primary cultured mesenteric artery smooth muscle cells for fluorescent imaging and physiological studies. Nat. Protoc. 1 (2006) 2681-2687
10. Guilluy C., Sauzeau V., Rolli-Derkinderen M., Guerin P., Sagan C., Pacaud P., and Loirand G. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br. J. Pharmacol. 146 (2005) 1010-1018
11. Hanze J., Weissmann N., Grimminger F., Seeger W., and Rose F. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb. Haemost. 97 (2007) 774-787
12. Hassoun P.M. Deciphering the "matrix" in pulmonary vascular remodelling. Eur. Respir. J. 25 (2005) 778-779
13. Kuzuya M., Kanda S., Sasaki T., Tamaya-Mori N., Cheng X.W., Itoh T., Itohara S., and Iguchi A. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 108 (2003) 1375-1381
14. Lepetit H., Eddahibi S., Fadel E., Frisdal E., Munaut C., Noel A., Humbert M., Adnot S., D'Ortho M.P., and Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 25 (2005) 834-842
15. Martin K.B., Klinger J.R., and Rounds S.I. Pulmonary arterial hypertension: new insights and new hope. Respirology 11 (2006) 6-17
16. McNamara P.J., Murthy P., Kantores C., Teixeira L., Engelberts D., Van Vliet T., Kavanagh B.P., and Jankov R.P. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am. J. Physiol. Lung Cell Mol. Physiol. 21 (2007) 21
17. Morrell N.W., Higham M.A., Phillips P.G., Shakur B.H., Robinson P.J., and Beddoes R.J. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir. Res. 6 (2005) 88
18. Murata T., Kinoshita K., Hori M., Kuwahara M., Tsubone H., Karaki H., and Ozaki H. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2335-2342
19. Nagaoka T., Gebb S.A., Karoor V., Homma N., Morris K.G., McMurtry I.F., and Oka M. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J. Appl. Physiol. 100 (2006) 996-1002
20. Oka M., Homma N., Taraseviciene-Stewart L., Morris K.G., Kraskauskas D., Burns N., Voelkel N.F., and McMurtry I.F. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ. Res. 100 (2007) 923-929
21. Paraskevas K.I., Athyros V.G., Briana D.D., Kakafika A.I., Karagiannis A., and Mikhailidis D.P. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr. Drug Targets 8 (2007) 942-951
22. Rikitake Y., and Liao J.K. Rho GTPases, statins, and nitric oxide. Circ. Res. 97 (2005) 1232-1235
23. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Samidurai A., Pullamsetti S., Weissmann N., Schudt C., Ermert L., Seeger W., and Grimminger F. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ. Res. 94 (2004) 1101-1108
24. Semenza G.L. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest 128 (2005) 592S-594S
25. Somerville R.P., Oblander S.A., and Apte S.S. Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 4 (2003) 216
26. Stenmark K.R., Fagan K.A., and Frid M.G. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 99 (2006) 675-691
27. Touyz R.M., and Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. 52 (2000) 639-672
28. Xing X.Q., Gan Y., Wu S.J., Chen P., Zhou R., and Xiang X.D. Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway. Med. Hypotheses 68 (2007) 1108-1113